Co-Administration of Mirdametinib and Lifirafenib for Use in Treating Cancers
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,667,560 | Co-Administration of Mirdametinib and Lifirafenib for Use in Treating Cancers In force · High confidence | BeiGene, Ltd. | In force | High confidence |
1 of 1 record shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.